Results 161 to 170 of about 1,457,300 (387)
Immunology of SARS-CoV-2 infection in children
Nature Immunology, 2022 J. Chou, P. Thomas, A. Randolph
semanticscholar +1 more source
Shared Genetic Effects and Antagonistic Pleiotropy Between Multiple Sclerosis and Common Cancers
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective Epidemiologic studies have reported inconsistent altered cancer risk in individuals with multiple sclerosis (MS). Factors such as immune dysregulation, comorbidities, and disease‐modifying therapies may contribute to this variability.
Asli Buyukkurt +5 more
wiley +1 more source
Experimental immunology<br>Immunosuppressive effect of systemic administration of <i>Lactobacillus rhamnosus</i> KL37C-derived exopolysaccharide on the OVA-specific humoral response [PDF]
, 2013 Marta Ciszek‐Lenda +5 more
openalex +1 more source
The immunology of rheumatoid arthritis
Nature Immunology, 2020 C. Weyand, J. Goronzy
semanticscholar +1 more source
Real‐World Performance of CSF Kappa Free Light Chains in the 2024 McDonald Criteria
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective Kappa free light chains (KFLCs) in the cerebrospinal fluid (CSF) have a similar performance to CSF‐restricted oligoclonal bands (OCB) for multiple sclerosis (MS) diagnosis. To help with implementation, we set out to resolve several remaining uncertainties: (1) performance in a real‐world cohort and the 2024 McDonald criteria; (2 ...
Maya M. Leibowitz +11 more
wiley +1 more source
Bioinformatics in molecular immunology laboratories demonstrated: Modeling an anti-CMV scFv antibody [PDF]
, 2006 Kek Heng Chua, Rofina Yasmin Othman
openalex +1 more source
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective To determine the concentration of glial fibrillary acidic protein (GFAP) in cerebrospinal fluid (CSF) and plasma in Alexander disease (AxD) and whether GFAP levels are predictive of disease phenotypes. Methods CSF and plasma were collected (longitudinally when available) from AxD participants and non‐AxD controls.
Amy T. Waldman +9 more
wiley +1 more source